Zobrazeno 1 - 10
of 305
pro vyhledávání: '"Radical cure"'
Autor:
Nada Abla, Anne Claire Marrast, Elodie Jambert, Naomi Richardson, Stephan Duparc, Lisa Almond, Karen Rowland Yeo, Xian Pan, Joel Tarning, Ping Zhao, Janice Culpepper, Catriona Waitt, Charlotte Koldeweij, Susan Cole, Andrew S. Butler, Sonia Khier, Jörg J. Möhrle, Myriam El Gaaloul
Publikováno v:
Malaria Journal, Vol 23, Iss 1, Pp 1-12 (2024)
Abstract Plasmodium vivax malaria remains a global health challenge, with approximately 6.9 million estimated cases in 2022. The parasite has a dormant liver stage, the hypnozoite, which reactivates to cause repeated relapses over weeks, months, or y
Externí odkaz:
https://doaj.org/article/45b60ab3d99845c694b1be738e16f7c1
Autor:
Raman Sharma, Hema Sharma, Siôn Jones, Isabelle Borghini-Fuhrer, Gonzalo J. Domingo, Rachel A. Gibson, Katie Rolfe, Lionel Tan, Ioana Gabriela Fiţa, Chao Chen, Panayota Bird, Anup Pingle, Stephan Duparc
Publikováno v:
Malaria Journal, Vol 23, Iss 1, Pp 1-6 (2024)
Abstract A single 300 mg dose of tafenoquine (an 8-aminoquinoline), in combination with a standard 3-day course of chloroquine, is approved in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged
Externí odkaz:
https://doaj.org/article/8e4d2be46a454fcaaae784e04ad2fa94
Autor:
Dysoley Lek, Yu-Cheng Tsai, Jillian Hirano, Siv Sovannaroth, Voeurng Bunreth, Prak Vonn, Or Vannthen, Tol Bunkea, Top Samphornarann, Nguon Sokomar, Mak Sarath, Soy Ty Kheang, Evelyn Wong, Michelle K. Burbach, Jayme Hughes, Huy Rekol
Publikováno v:
Malaria Journal, Vol 23, Iss 1, Pp 1-13 (2024)
Abstract Background Cambodia aims to eliminate all forms of malaria by 2025. In 2020, 90% of all malaria cases were Plasmodium vivax. Thus, preventing P. vivax and relapse malaria is a top priority for elimination. 14-day primaquine, a World Health O
Externí odkaz:
https://doaj.org/article/2c7c141c70024d6f81d5a5f299896045
Autor:
Sundus Shafat Ahmad, Reena Verma, Robert J. Commons, Nitika, Sauman Singh-Phulgenda, Rutuja Chhajed, Praveen K. Bharti, Beauty Behera, Syed Mohammad Naser, Salil Kumar Pal, Parinita Halder Ranjit, Rajendra Kumar Baharia, Bhavin Solanki, K. J. Upadhyay, Philippe J. Guerin, Amit Sharma, Ric N. Price, Manju Rahi, Kamala Thriemer
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-14 (2024)
Abstract Background Plasmodium vivax remains a major challenge for malaria control and elimination due to its ability to cause relapsing illness. To prevent relapses the Indian National Center for Vector Borne Diseases Control (NCVBDC) recommends tre
Externí odkaz:
https://doaj.org/article/396a7370c1ca4051a4cc63cd2dce68ce
Autor:
Hui Liu, Jian-Wei Xu, Dao-Wei Deng, Bi Yaw, Hkawn Shawng Nbwi, Chun Wei, Xing-Wu Zhou, Jian-Xiong Li
Publikováno v:
Parasites & Vectors, Vol 17, Iss 1, Pp 1-10 (2024)
Abstract Background Plasmodium vivax malaria, with the widest geographic distribution, can cause severe disease and death. Primaquine is the main licensed antimalarial drug that can kill hypnozoites. The dose-dependent acute haemolysis in individuals
Externí odkaz:
https://doaj.org/article/d7f2fe6e53ce4c80b47731c81ce94cd5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
James A Watson, Robert J Commons, Joel Tarning, Julie A Simpson, Alejandro Llanos Cuentas, Marcus VG Lacerda, Justin A Green, Gavin CKW Koh, Cindy S Chu, François H Nosten, Richard N Price, Nicholas PJ Day, Nicholas J White
Publikováno v:
eLife, Vol 13 (2024)
In our recent paper on the clinical pharmacology of tafenoquine (Watson et al., 2022), we used all available individual patient pharmacometric data from the tafenoquine pre-registration clinical efficacy trials to characterise the determinants of ant
Externí odkaz:
https://doaj.org/article/a448849101ae42ba942170feabc3d8bf
Autor:
Raman Sharma, Chao Chen, Lionel Tan, Katie Rolfe, Ioana-Gabriela Fiţa, Siôn Jones, Anup Pingle, Rachel A Gibson, Navin Goyal, Hema Sharma, Panayota Bird
Publikováno v:
eLife, Vol 13 (2024)
A single 300 mg dose of tafenoquine, in combination with chloroquine, is currently approved in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged ≥16 years. Recently, however, Watson et al. s
Externí odkaz:
https://doaj.org/article/b532a7338996414085af7657c6237fea
Autor:
Sasithon Pukrittayakamee, Podjanee Jittamala, James A Watson, Borimas Hanboonkunupakarn, Pawanrat Leungsinsiri, Kittiyod Poovorawan, Kesinee Chotivanich, Germana Bancone, Cindy S Chu, Mallika Imwong, Nicholas PJ Day, Walter RJ Taylor, Nicholas J White
Publikováno v:
eLife, Vol 12 (2024)
Background: Primaquine is an 8-aminoquinoline antimalarial. It is the only widely available treatment to prevent relapses of Plasmodium vivax malaria. The 8-aminoquinolines cause dose-dependent haemolysis in glucose-6-phosphate dehydrogenase deficien
Externí odkaz:
https://doaj.org/article/e585cfc833ba4c7cb5854b2dab312fc7
Autor:
Annisa Rahmalia, Jeanne Rini Poespoprodjo, Chandra U. R. Landuwulang, Maya Ronse, Enny Kenangalem, Faustina H. Burdam, Kamala Thriemer, Angela Devine, Ric N. Price, Koen Peeters Grietens, Benedikt Ley, Charlotte Gryseels
Publikováno v:
Malaria Journal, Vol 22, Iss 1, Pp 1-16 (2023)
Abstract Background Reducing the risk of recurrent Plasmodium vivax malaria is critical for malaria control and elimination. Primaquine (PQ) is the only widely available drug against P. vivax dormant liver stages, but is recommended as a 14-day regim
Externí odkaz:
https://doaj.org/article/6da2e98274d749c993482c5971e4eea8